A similar design (phase 1b/2) to combat “metastatic castrate resistant prostate cancer” has been posted using etrumadenant, AB122 and/or an inhibitor of the enzyme producing adenosine from AMP (CD73/5′-nucleotidase) (CTg Identifier: NCT04381832). This evidence concerns the gene NT5E and prostate carcinoma.